ScreenerHero

PGEN Precigen, Inc.

NAS · US · Healthcare · Biotechnology · precigen.com
7.600USD+0.80%Mkt Cap: 2.71B $P/E: —

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious di…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap2.71B USD
Enterprise Value2.76B USD
Revenue (TTM)85.72M USD
Gross Profit4.86M USD
Net Income (TTM)-250.64M USD
Revenue/Share0.25 USD
Last Price7.600 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees160
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-34.32
PEG—
EV/EBITDA-78.15
EV/Revenue32.24
P/S31.40
P/B61.89
EPS (TTM)-1.01
EPS (Forward)-0.22
52W Range
2.99077% of range8.980
52W High8.980 USD
52W Low2.990 USD
Profitability
Gross Margin50.20%
Oper. Margin41.18%
EBITDA Margin-41.25%
Profit Margin-2588.21%
ROE-1198.61%
ROA-161.18%
Growth
Revenue Growth6322.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-87.83M USD
CapEx (TTM)2.00M USD
FCF Margin-116.78%
FCF Yield-3.69%
Net Debt60.14M USD
Net Debt/EBITDA-1.70
Balance Sheet
Debt/Equity4.70
Current Ratio4.58
Quick Ratio3.76
Book Value/Sh0.12 USD
Cash/Share0.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.65 USD
Upside (mean)+79.6%
Target Range11.00 USD – 17.95 USD
11.00+79.6% to mean17.95
# Analysts3
Ownership
Shares Out.356.51M
Float194.60M
Insiders12.64%
Institutions72.83%
Short Interest
Short Ratio10.4d
Short % Float21.66%
Short % Out.11.81%
Shares Short42.28M
Short (prev mo.)42.24M
Technical
SMA 507.075 (+7.4%)
SMA 2005.024 (+51.3%)
Beta0.92
S&P 52W Chg16.45%
Avg Vol (30d)4.92M
Avg Vol (10d)6.26M
Technical Indicators
RSI (14)52.5
MACD0.2778
MACD Signal0.3507
MACD Hist.-0.0728
BB Upper8.693 USD
BB Middle7.561 USD
BB Lower6.428 USD
BB Width29.97%
ATR (14)0.4748 USD
Vol Ratio (20d)0.74x